PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of aapspharmspringer.comThis journalToc AlertsSubmit OnlineOpen Choice
 
AAPS PharmSciTech. 2003 September; 4(3): 110–115.
Published online 2003 August 7. doi:  10.1208/pt040343
PMCID: PMC2750636

Effect of microenvironment pH of swellable and erodable buffered matrices on the release characteristics of diclofenac sodium

Abstract

The aim of this work is to design pH-dependent swellable and erodable-buffered matrices and to study the effect of the microenvironment pH on the release pattern of diclofenac sodium. Buffered matrix tablets containing diclofenac sodium, physically mixed with hydrophilic polymer (hydroxypropyl methylcellulose [HPMC]) and pH-dependent solubility polymer (Eudragit L100-55) were prepared with different microenvironment pHs. The release of diclofenac sodium from the buffer matrices was studied in phosphate buffer solutions of pH 5.9 and 7.4. The swelling and erosion matrices containing only HPMC and Eudragit L100-55 were studied in phosphate buffer solution of pH similar to the microenvironment pHs of the matrices. Drug release from matrices was found to be linear as a function of time. Amount of drug released was found to be higher in the medium of pH 7.4 than that of pH 5.9. The rate of drug release increased with the increase of the microenvironment pH of the matrices as determined from the slope. The pattern of drug release did not change with the change of microenvironment pH. The swelling and erosion occurred simultaneously from matrices made up of HPMC and Eudragit L100-55. Both extent of swelling and erosion increased with increase of the medium pH. It was concluded from this study that changing the pH within the matrix influenced the rate of release of the drug without affecting the release pattern.

Keywords: controlled release, buffered matrix, swelling, erosion, sustained release

Full Text

The Full Text of this article is available as a PDF (281K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
1. Chien YW. Novel Drug Delivery Systems. 2nd ed. New York, NY: Marcel Dekkar; 1992. Fundamentals of rate-controlled drug delivery; pp. 43–137.
2. Gao P, Meury RH. Swelling hydroxypropyl methylcelloluse matrix tablets. 1. Characterization of swelling using a novel optical imaging method. J Pharm Sci. 1996;85(7):725–731. doi: 10.1021/js950458c. [PubMed] [Cross Ref]
3. Ammar HO, Khalil RM. Preparation and evaluation of sustained-release solid dispersions of drugs with Eudragit polymers. Drug Dev Ind Pharm. 1997;23(11):1043–1054. doi: 10.3109/03639049709150492. [Cross Ref]
4. Kislalioglu MS, Khan MA, Blount C, Goettch RW, Bolton S. Physical characterization and dissolution properties of ibuprofen: eudragit coprecipitates. J Pharm Sci. 1991;80:799–804. doi: 10.1002/jps.2600800820. [PubMed] [Cross Ref]
5. Wade A, Weller PJ, editors. Handbook of Pharmaceutical Excipients. London, UK: Pharmaceutical Press; 1994. pp. 362–366.
6. Bainchini R, Resciniti M, Vecchio C. Technological evaluation of aqueous enteric coated systems with and without insoluble additives. Drug Dev Ind Pharm. 1991;17:1779–1794. doi: 10.3109/03639049109074392. [Cross Ref]
7. Durig T, Venkatesh GM, Fassihi R. An investigation into the erosion behavior of high drug-load (85%) particulate system designed for an extended-release matrix tablet: analysis of erosion kinetics in conjunction with variation in lubrication, porosity, and compaction rate. J Pharm Pharmacol. 1999;51:1085–1092. doi: 10.1211/0022357991776769. [PubMed] [Cross Ref]
8. Mehta KA, Kislalioglu MS, Phuapradit W, Malick AW, Shah NH. Release performance of a poorly soluble drug from a novel, Eudragit-based multi-unit erosion matrix. Int J Pharm. 2001;213:7–12. doi: 10.1016/S0378-5173(00)00594-9. [PubMed] [Cross Ref]
9. Khan MZI, Stedul HP, Kurjakovic N. A pH-dependent colon targeted oral drug delivery system using methacrylic acid copolymers. II. Manipulation of drug release using Eudragit L100 and Eudragit S100 combinations. Drug Dev Ind Pharm. 2000;26(5):549–554. doi: 10.1081/DDC-100101266. [PubMed] [Cross Ref]
10. Terao T, Matsuda K, Shougi H. Improvement in site specific intestinal absorption of furocemide by Eudragit L100-55. J Pharm Pharmacol. 2001;53:433–440. doi: 10.1211/0022357011775721. [PubMed] [Cross Ref]
11. Lee PI. Diffusional release of a solute from a polymeric matrix—approximate analytical solutions. J Memb Sci. 1980;7:255–275. doi: 10.1016/S0376-7388(00)80474-3. [Cross Ref]
12. Blase CM, Peck GE. Development of a unique buffered matrix aspirin tablet. Drug Dev Ind Pharm. 1992;18(8):869–893. doi: 10.3109/03639049209069304. [Cross Ref]
13. Finne U, Vaisanen V, Urtti A. Modification of ocular and systemic absorption of timolol from ocular inserts by a buffering agent and a vasoconstrictor. Int J Pharm. 1990;65:19–27. doi: 10.1016/0378-5173(90)90004-N. [Cross Ref]
14. Martin A, Bustamante P, Chun A, editors. Buffered and isotonic solutions. 4th ed. Philadelphia, PA: Lea & Febiger; 1993. pp. 169–189.
15. Abrahamsson B, Alpesten M, Bake B, Larsson A, Sjogren J. In vitro and in vivo erosion of two different hydrophilic gel matrix tablets. Eur J Pharm Biopharm. 1998;46:69–75. doi: 10.1016/S0939-6411(98)00002-2. [PubMed] [Cross Ref]
16. Sheu M, Chou H, Kao C, Liu C, Sokoloski T. Dissolution of diclofenac sodium from matrix tablet. Int J Pharm. 1992;85:57–63. doi: 10.1016/0378-5173(92)90134-N. [Cross Ref]
17. Carelli V, Colo G, Nannipieri E, Poli B, Serafini MF. Poly(oxyethylene)-Poly(methacrylic acid-co-methyl methacrylate) compounds for site specific per oral delivery. Int J Pharm. 2000;202:103–112. doi: 10.1016/S0378-5173(00)00429-4. [PubMed] [Cross Ref]
18. Bettini R, Colombo P, Peppas NA. Solubility effects on drug transport through pH sensitive swelling-controlled release system: transport of theophylline and metaclopramide monohydrochloride. J Control Release. 1995;37:150–111. doi: 10.1016/0168-3659(95)00069-K. [Cross Ref]
19. Kim CJ, Lee PI. Hydrophobic anionic gel beads for swelling-controlled drug delivery. Pharm Res. 1992;9:195–199. doi: 10.1023/A:1018929205254. [PubMed] [Cross Ref]
20. Kim C. Application of shrinking-core model for ionization of hydrophobic ionic beads. Drug Dev Ind Pharm. 1996;22:307–311. doi: 10.3109/03639049609041994. [Cross Ref]
21. Cameron CG, McGinity JW. Controlled release theophylline tablet formulations containing acrylic resins. Part 2. Combination resin formulations. Drug Dev Ind Pharm. 1987;13(8):1409–1427. doi: 10.3109/03639048709068383. [Cross Ref]
22. Avdeef A, Berger CM, Brownell C. pH-metric solubility. 2. Correlation between the acid-base titration and the saturation shake-flask solubility pH methods. Pharm Res. 2000;17:85–89. doi: 10.1023/A:1007526826979. [PubMed] [Cross Ref]
23. Sarjeev C, Saha RN. Formulation and comparative evaluation of controlled release diclofenac tablets prepared by matrixembedding technique, membrane barrier technique, and combination of the two. Drug Dev Res. 2001;53:1–8. doi: 10.1002/ddr.1162. [Cross Ref]
24. Padmalatha DK, Ranga Rao KV, Baveja S, Fathi M, Roth M. Zero-order release formulation of oxprenolol hydrochloride with swelling and erosion control. Pharm Res. 1989;6:313–317. doi: 10.1023/A:1015998424548. [PubMed] [Cross Ref]
25. Efentakis M, Koutlis A. Release of furosemide from multiple unit and single unit preparations containing different viscosity grades of sodium alginate. Pharm Dev Tech. 2001;6(1):91–98. doi: 10.1081/PDT-100000048. [PubMed] [Cross Ref]

Articles from AAPS PharmSciTech are provided here courtesy of American Association of Pharmaceutical Scientists